CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 16,577,600 shares, a growth of 25.8% from the October 15th total of 13,179,400 shares. Based on an average daily volume of 6,265,900 shares, the days-to-cover ratio is currently 2.6 days.
CytoDyn Stock Performance
Shares of CYDY stock opened at $0.12 on Friday. The company has a fifty day moving average price of $0.14 and a two-hundred day moving average price of $0.15. CytoDyn has a one year low of $0.11 and a one year high of $0.42.
CytoDyn (OTCMKTS:CYDY – Get Free Report) last announced its quarterly earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 EPS for the quarter.
CytoDyn Company Profile
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
See Also
- Five stocks we like better than CytoDyn
- Find and Profitably Trade Stocks at 52-Week Lows
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- What is Forex and How Does it Work?
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What is the Shanghai Stock Exchange Composite Index?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
